Rivaroxiban effective in treating COVID 19 patients: MICHELLE Trial

Published On 2022-02-08 12:23 GMT | Update On 2022-02-08 13:53 GMT

The covid pandemic has rained its havoc in the entire world. Millions of patients died and many more were discharged worldwide. Excessive thrombosis was the designated culprit for the morbidity and mortality. MICELLE trial was conducted to find out whether rivaroxiban which is a direct anticoagulant is useful in patients after hospitalization for covid-19 for improving their clinical outcomes without bleeding. This was a landmark trial.

The primary outcome reported symptomatic venous thromboembolism, venous thromboembolism-related death, bilateral venous thromboembolism, symptomatic arterial thromboembolism, myocardial infarction, non hemorrhagic stroke, major adverse limb event, or cardiovascular death at 35 days, was 3.14% in the rivaroxaban group compared with 9.43% in the control group. Among patients discharged after COVID-19 infection, rivaroxaban for 35 days was beneficial.

The trials main purpose was to evaluate rivaroxaban compared with control among patients discharged after hospitalization for coronavirus disease infection. Over 160 participants discharged after COVID-19 infection were randomized to rivaroxaban 10 mg daily, vs control. Rivaroxaban was associated with a reduction in clinical events without increasing major bleeding.

Full View

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Rivaroxiban effective in treating COVID 19 patients: MICHELLE Trial

Similar News

Alkem Launches 'PRAYAS': A Bold Step Toward Accessible Cancer Care

Microplastics Detected in Human Reproductive Fluids, Raising Fertility Concerns: Study Suggests

Early Bedtimes May Boost Physical Activity: Study Finds

Overemphasis on Weight Loss May Harm Patients: BMJ Study Finds

Weight-Loss Surgery Doubles Self-Esteem Scores: Study Finds

New HIV Vaccine Combines Adjuvants for Stronger, Longer Immune Response

Study Reveals How Coffee May Improve Longevity

Ajanta Pharma Launches Met XL AMT 25 mg a triple FDC for Uncontrolled Hypertension with CAD